Forme libre de curcumine optimisée pour une dégradation lente
- Allows slow breakdown by the body
- Mild dose-optimized curcumin from turmeric
- Remains in the bloodstream for up to 24 hours
CurcuVIVA™ provides an 80 mg maintenance dose of Longvida Optimized Curcumin for those with osteoarthritis, joint pain, chronic pain and more. Longvida Curcumin was specially formulated to provide a solution to the curcumin conundrum of low bioavailability, poor absorption and rapid breakdown. Although bioavailability and absorption help determine effectiveness, the key lies within its ability to remain free. This free state of curcumin is achieved due to the formula’s ability to avoid being rapidly broken down within the body. Because free curcumin retains its “unbroken” form, it is then taken up through the lymph system into the bloodstream where it is stable, concentrated, and retains maximum effectiveness for up to 24 hours.Curcumin not only provides relief from joint pain and arthritis, but has many other benefits. It supports digestion, liver and gallbladder health, carries antibacterial, antifungal and antiviral effects, and even promotes healthy cholesterol levels and cardiovascular health.
Serving Size: 1 Capsule
†Daily Value not established
Ingrédients non médicinaux : capsule (hypromellose, glycerin and water), Palmitate d'ascorbyle, lécithine de soja, maltodextrine, cellulose microcristalline, silice, acide stéarique, stéaryl fumarate de sodium.Contains: Soy.
Curcumin is currently being heavily studied for use as an adjunct to conventional cancer treatments. Unfortunately, most of the studies have noted minimal results despite promising in vitro and animal studies. Researchers have recognized that the cause for the poor results is curcumin’s poor bioavailability.BioavailabilityGota and colleagues did a safety and bioavailability study on healthy volunteers and patients with non-responsive bone cancer. Subjects were given doses between 400 and 1,200 mg of curcumin in solid lipid particle form (equivalent to 1 to 3 capsules of CurcuVIVA). All doses showed significant absorption into the bloodstream over 8 hours with no adverse events. This is especially significant since previous studies giving 8,000-12,000 mg of pure regular curcumin barely showed any blood levels or clinical improvements. In addition, the 1,200 mg dose produced blood levels of curcumin necessary to reduce isoprostanes, TNF-α, and amyloid-β, which are markers for diseases like cancer and Alzheimer’s disease.Amyloid-β ReductionsThere is also significant interest in its ability to reduce amyloid-β plaque, which is thought to be a causative factor of Alzheimer’s disease. In vitro and animal studies have shown that curcumin can significantly reduce levels of amyloid-β and preserve Alzheimer model animal memory. Finally, a recent human study has shown that just 80 mg of curcumin can reduce amyloid-β in humans. The curcumin that was finally able to do so was Longvida® curcumin SLP, and in just one month.Longvida® Curcumin in HumansA human trial on curcumin showed statistically significant effects on clinical endpoints in a healthy population. The fact that such a low dose (80 mg) was needed to achieve effects in only 30 days is an interesting and unique finding as well, and adds to the substantial amount of pharmacokinetic and pharmacodynamic data compiled on Longvida®. The results of the study suggest that curcumin can produce beneficial effects in people who are without immediate disease states. The study was conducted on 38 healthy middle aged people between the age of 40 and 60 who were either given a dose of 80 mg/day of Longvida® curcumin extract for four weeks or were a part of the 19 person placebo group. The study is particularly interesting because the relatively small dose of curcumin, from Longvida® which was used, exerted a variety of health promoting effects leading researchers to presume that a significant amount of the curcumin was absorbed, although not tested directly.Blood sample readings collected from test subjects to assess nitric oxide and sICAM molecules which are relevant to assessing cardiovascular risk and related to blood pressure and atherosclerosis, were notably affected by the curcumin. Both readings corresponded to a decreased risk of cardiovascular disease. The study also indicated that curcumin may have a positive effect on liver health maintenance as was noted from the reduction of indicators used to mark liver injury. Participants had lowered levels of triglycerides which relates to other research demonstrating that cholesterol could potentially be lowered in relatively healthy persons given higher dosages of the substance, thus benefiting those with or at risk of having cardiovascular disease.Interestingly, other markers of inflammation and free radicals/toxic species that cause inflammation and damage to cells were also significantly lowered. Both direct and indirect antioxidant actions of curcumin were evident in the subjects; these findings are consistent with in vitro and animal studies used to measure increases in curcumin induced antioxidant enzyme activity.
Please select a start rating